Munger Mark A, Gardner Stephanie F, Ateshkadi Arasb, Rabetoy Gary M, Barri Yoursi M, Stoddard Gregory J, Cheung Alfred K
Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, Utah 84112-5820, USA.
Pharmacotherapy. 2008 Jul;28(7):834-42. doi: 10.1592/phco.28.7.834.
To determine whether coadministration of misoprostol with the nonsteroidal antiinflammatory drug diclofenac lessens the increase in blood pressure and improves the alterations in renal hemodynamics induced by diclofenac.
Prospective, randomized, double-blind, placebo-controlled, crossover study.
Two university research centers.
Nineteen senior (mean age 62 yrs [range 55-73 yrs]), salt-sensitive patients with stage 1 or 2 hypertension.
After a 3-week antihypertensive withdrawal lead-in phase, patients received either diclofenac 75 mg alone or diclofenac 75 mg plus misoprostol 200 microg twice/day for 14 days. After a 10-day washout period, patients received the alternate treatment.
Blood pressure was measured by 24-hour ambulatory blood pressure monitoring, effective renal plasma flow (ERPF) rate was determined by para-aminohippurate clearance, and glomerular filtration rate (GFR) was measured by iothalamate clearance. Mean arterial pressure (MAP = diastolic blood pressure + 0.33[systolic - diastolic blood pressure]) and rate-pressure product (RPP = systolic blood pressure x heart rate x 10(-2)) were also used to compare treatment groups. Diclofenac alone increased MAP by a mean +/- SEM of 5.0 +/- 1.0 mm Hg and RPP by 337 +/- 181 units compared with baseline. The ERPF rate and GFR decreased by 40.5 +/- 26.9 ml/minute and 14.1 +/- 6.5 ml/minute, respectively. Diclofenac plus misoprostol decreased the diclofenac-induced increase in MAP by 3.3 +/- 1.0 mm Hg (95% confidence interval [CI] 1.1-5.3 mm Hg, p=0.004) and decreased the RPP by 724 +/- 238 units (95% CI 225-1223 units, p=0.007). The ERPF rate increased by 56.1 +/- 35.0 ml/minute (95% CI -24.7-137.0 ml/min, p=0.15) and GFR by 18.1 +/- 7.1 ml/minute (95% CI 1.9-34.5 ml/min, p=0.03). Diclofenac alone was relatively well tolerated; no adverse effects were reported with diclofenac plus misoprostol.
In senior salt-sensitive patients with hypertension, coadministration of misoprostol with diclofenac attenuated the blood pressure elevation and renal vasoconstrictive effects of diclofenac and was well tolerated.
确定米索前列醇与非甾体抗炎药双氯芬酸联合使用是否能减轻双氯芬酸引起的血压升高,并改善其所致的肾血流动力学改变。
前瞻性、随机、双盲、安慰剂对照、交叉研究。
两个大学研究中心。
19名老年(平均年龄62岁[范围55 - 73岁])、盐敏感的1或2期高血压患者。
在为期3周的降压洗脱导入期后,患者接受单独使用双氯芬酸75毫克或双氯芬酸75毫克加米索前列醇200微克,每日两次,共14天。经过10天的洗脱期后,患者接受交替治疗。
通过24小时动态血压监测测量血压,通过对氨基马尿酸清除率测定有效肾血浆流量(ERPF),通过碘他拉酸盐清除率测量肾小球滤过率(GFR)。还使用平均动脉压(MAP = 舒张压 + 0.33×[收缩压 - 舒张压])和率压乘积(RPP = 收缩压×心率×10⁻²)来比较治疗组。与基线相比,单独使用双氯芬酸使MAP平均升高5.0±1.0毫米汞柱,RPP升高337±181单位。ERPF率和GFR分别下降40.5±26.9毫升/分钟和14.1±6.5毫升/分钟。双氯芬酸加米索前列醇使双氯芬酸引起的MAP升高降低3.3±1.0毫米汞柱(95%置信区间[CI] 1.1 - 5.3毫米汞柱,p = 0.004),使RPP降低724±238单位(95% CI 225 - 1223单位,p = 0.007)。ERPF率升高56.1±35.0毫升/分钟(95% CI - 24.7 - 137.0毫升/分钟,p = 0.15),GFR升高18.1±7.1毫升/分钟(95% CI 1.9 - 34.